Gyre Therapeutics (GYRE) Other Non Operating Income (2015 - 2026)
Gyre Therapeutics (GYRE) reported Other Non Operating Income of $29000.0 for Q1 2026, down 72.9% year-over-year from $107000.0 in Q1 2025, and up 101.32% on a QoQ basis from -$2.2 million in Q4 2025.
Gyre Therapeutics (GYRE) has 12 years of Other Non Operating Income data on file, last reported at $29000.0 in Q1 2026.
- Quarterly Other Non Operating Income fell 72.9% year-over-year to $29000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.6 million (up 5.44% YoY) and the FY2025 annual result came in at -$1.5 million, up 9.28% from the prior year.
- Other Non Operating Income improved to $29000.0 in Q1 2026 per GYRE's latest filing, from -$2.2 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at $858000.0 in Q4 2022 and bottomed at -$2.2 million in Q4 2025.
- The 5-year median for Other Non Operating Income is -$1000.0 (2022), against an average of -$185470.6.
- The widest annual swing landed in 2022, when Other Non Operating Income soared 4390.0%; it then sank 133200.0% in 2023.
- Tracing GYRE's Other Non Operating Income over 5 years: stood at $858000.0 in 2022, then sank by 127.62% to -$237000.0 in 2023, then tumbled by 589.45% to -$1.6 million in 2024, then tumbled by 34.27% to -$2.2 million in 2025, then soared by 101.32% to $29000.0 in 2026.
- Per Business Quant, the three latest GYRE Other Non Operating Income figures stand at $29000.0 (Q1 2026), -$2.2 million (Q4 2025), and $727000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29,000.00 |
| Dec 31, 2025 | -2.19 Mn |
| Sep 30, 2025 | 727,000.00 |
| Jun 30, 2025 | -145,000.00 |
| Mar 31, 2025 | 107,000.00 |
| Dec 31, 2024 | -1.63 Mn |
| Sep 30, 2024 | -75,000.00 |
| Jun 30, 2024 | -72,000.00 |
| Mar 31, 2024 | 122,000.00 |
| Dec 31, 2023 | -237,000.00 |
| Sep 30, 2023 | -1.33 Mn |
| Jun 30, 2023 | 629,000.00 |
| Mar 31, 2023 | 66,000.00 |
| Dec 31, 2022 | 858,000.00 |
| Sep 30, 2022 | -1,000.00 |
| Jun 30, 2022 | 17,000.00 |
| Mar 31, 2022 | -17,000.00 |
| Dec 31, 2021 | -20,000.00 |
| Sep 30, 2021 | -16,000.00 |
| Jun 30, 2021 | -25,000.00 |
| Mar 31, 2021 | -17,000.00 |
| Dec 31, 2020 | -71,000.00 |
| Sep 30, 2020 | -7,000.00 |
| Jun 30, 2020 | 15,000.00 |
| Mar 31, 2020 | 679,000.00 |
| Dec 31, 2019 | 2,000.00 |
| Sep 30, 2019 | -71,000.00 |
| Dec 31, 2018 | 153,000.00 |
| Sep 30, 2018 | -1,000.00 |
| Jun 30, 2018 | 30,000.00 |
| Mar 31, 2018 | 1.47 Mn |
| Dec 31, 2017 | -186,000.00 |
| Sep 30, 2017 | 85,000.00 |
| Jun 30, 2017 | 14,000.00 |
| Mar 31, 2017 | 16,000.00 |
| Dec 31, 2016 | -77,000.00 |
| Sep 30, 2016 | 38,000.00 |
| Jun 30, 2016 | 16,000.00 |
| Mar 31, 2016 | 20,000.00 |
| Dec 31, 2015 | -93,000.00 |
| Sep 30, 2015 | -467,000.00 |